Sakoff JA - Search Results

1

The first two cantharidin analogues displaying PP1 selectivity.

McCluskey A, Keane MA, Walkom CC, Bowyer MC, Sim AT, Young DJ, Sakoff JA. McCluskey A, et al. Among authors: sakoff ja. Bioorg Med Chem Lett. 2002 Feb 11;12(3):391-3. doi: 10.1016/s0960-894x(01)00777-6. Bioorg Med Chem Lett. 2002. PMID: 11814804

2

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents.

Aputen AD, Elias MG, Gilbert J, Sakoff JA, Gordon CP, Scott KF, Aldrich-Wright JR. Aputen AD, et al. Among authors: sakoff ja. Cancers (Basel). 2023 Apr 26;15(9):2460. doi: 10.3390/cancers15092460. Cancers (Basel). 2023. PMID: 37173934 Free PMC article.

3

Synthesis and Characterisation of Fluorescent Novel Pt(II) Cyclometallated Complexes with Anticancer Activity.

McGhie BS, Sakoff J, Gilbert J, Gordon CP, Aldrich-Wright JR. McGhie BS, et al. Int J Mol Sci. 2023 Apr 28;24(9):8049. doi: 10.3390/ijms24098049. Int J Mol Sci. 2023. PMID: 37175756 Free PMC article.

4

Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates.

Aputen AD, Elias MG, Gilbert J, Sakoff JA, Gordon CP, Scott KF, Aldrich-Wright JR. Aputen AD, et al. Among authors: sakoff ja. Molecules. 2022 Oct 21;27(20):7120. doi: 10.3390/molecules27207120. Molecules. 2022. PMID: 36296713 Free PMC article.

5

Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells.

Khoury A, Sakoff JA, Gilbert J, Karan S, Gordon CP, Aldrich-Wright JR. Khoury A, et al. Among authors: sakoff ja. Pharmaceutics. 2022 Dec 12;14(12):2780. doi: 10.3390/pharmaceutics14122780. Pharmaceutics. 2022. PMID: 36559273 Free PMC article.

6

Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.

McCluskey A, Bowyer MC, Collins E, Sim ATR, Sakoff JA, Baldwin ML. McCluskey A, et al. Among authors: sakoff ja. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1687-90. doi: 10.1016/s0960-894x(00)00323-1. Bioorg Med Chem Lett. 2000. PMID: 10937725

7

Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?

McCuskey A, Keane MA, Mudgee LM, Sim AT, Sakoff J, Quinn RJ. McCuskey A, et al. Eur J Med Chem. 2000 Oct;35(10):957-64. doi: 10.1016/s0223-5234(00)00186-0. Eur J Med Chem. 2000. PMID: 11121622

8

Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.

McCluskey A, Walkom C, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA. McCluskey A, et al. Among authors: sakoff ja. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2941-6. doi: 10.1016/s0960-894x(01)00594-7. Bioorg Med Chem Lett. 2001. PMID: 11677131

9

Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.

McCluskey A, Sim AT, Sakoff JA. McCluskey A, et al. Among authors: sakoff ja. J Med Chem. 2002 Mar 14;45(6):1151-75. doi: 10.1021/jm010066k. J Med Chem. 2002. PMID: 11881984 Review. No abstract available.

10

Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues.

Sakoff JA, Ackland SP, Baldwin ML, Keane MA, McCluskey A. Sakoff JA, et al. Invest New Drugs. 2002 Feb;20(1):1-11. doi: 10.1023/a:1014460818734. Invest New Drugs. 2002. PMID: 12003183

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters